Table 1.
Baseline characteristics of the cohortA
| Characteristic | Guideline-recommen ded dosing (n= 42) |
Lower dosing (n= 50) |
p-value |
|---|---|---|---|
|
|
|||
| Male gender (%) | 88 | 92 | 0.53 |
| Age (years) | 77 (69, 84) | 74 (68, 78) | 0.04 |
| Race (%) | 0.54 | ||
| Caucasian | 71 | 80 | |
| African American | 17 | 10 | |
| Hispanic | 10 | 8 | |
| Other | 2 | 0 | |
| Height (cm) | 173 (168, 180) | 178 (170, 183) | 0.02 |
| Weight (kg) | 62 (57, 73) | 86 (74, 99) | <0.001 |
| Serum Creatinine (mg/dl) | 1.1 (0.8, 1.4) | 1.0 (0.8, 1.3) | 0.49 |
| Creatinine Clearance (ml/min) | 48 (39, 67) | 64 (53, 79) | 0.002 |
| Charlson comorbity index > 5 | 10 | 14 | 0.51 |
| Pitt Bacteremia Score | 2 (1, 3) | 2 (1, 3) | 0.33 |
| Nephrotoxins (%) | 45 | 44 | 0.90 |
| Infection Source (%) | 0.11 | ||
| Bloodstream catheter related | 26 | 26 | |
| Pulmonary | 24 | 28 | |
| Skin/muscle | 14 | 22 | |
| Genitourinary | 14 | 6 | |
| Osteomyelitis | 0 | 2 | |
| Gastrointestinal | 0 | 2 | |
| Other | 22 | 14 | |
| Length of hospital stay (days) | 17 (9, 42) | 22 (9, 34) | 0.99 |
| Intensive Care Unit Length of stay (days) | 0 (0, 11) | 3 (0, 16) | 0.46 |
| Initial vancomycindose (mg/kg/day) | 31 (25, 35) | 22 (18, 25) | <0.001 |
| Initial vancomycin trough (mg/l) | 15 (11, 19) | 12 (9, 18) | 0.46 |
A
= Results are presented as median (interquartile range) unless otherwise noted